$GILD News More positive tests for hep C drug bo
Post# of 88935
Posted On: 01/31/2014 4:05:56 PM
$GILD News
More positive tests for hep C drug boost AbbVie and Enanta shares 10:52 a.m. Today - blogs.marketwatch.com
Cash ain’t trash 1:55 p.m. Jan. 28, 2014 - The Trading Deck
Beware the dead-cat bounce 1:24 p.m. Jan. 28, 2014 - Michael Ashbaugh
Beware the dead-cat bounce 1:06 p.m. Jan. 28, 2014 - Michael Ashbaugh
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Are the prevailing technicals bullish, or bearish? 11:54 a.m. Jan. 17, 2014 - Michael Ashbaugh
U.S. stocks drop on Goldman, Citi; Nasdaq edges up 4:07 p.m. Jan. 16, 2014 - Laura Mandaro
Nu Skin sinks on China probe; Best Buy hits 6-month low 4:04 p.m. Jan. 16, 2014 - Ben Eisen
S&P 500 drops from record, but Nasdaq ekes out gain: Stock market live blog recap 4:02 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Speculators turn the heat up to ‘soft boil’ 3:54 p.m. Jan. 16, 2014 - The Trading Deck
Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 3:09 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Earnings boost Micron, drag on Container Store 4:24 p.m. Jan. 8, 2014 - Ben Eisen
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
3 top trades for 2014 6:00 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - blogs.marketwatch.com
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Saumya Vaishampayan
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:18 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? 2:12 p.m. Today - TheStreet.com
Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences 10:07 a.m. Today - TheStreet.com
Gilead Sciences Inc Retains Buy Recommendation 9:00 a.m. Today - TheStreet.com
Idenix to Raise Funds, Shares up - Analyst Blog 5:20 p.m. Jan. 29, 2014 - Zacks.com
Why Caution Is Prevailing in Biotechs Into and After Earnings 11:29 a.m. Jan. 29, 2014 - 247WallSt.com
UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside 7:35 a.m. Jan. 29, 2014 - 247WallSt.com
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 29, 2014 - Zacks.com
6 Biotechnology Stocks to Buy Now 6:00 a.m. Jan. 29, 2014 - InvestorPlace.com
Don't Underestimate Amgen: Part 2A, Cardiovascular And Oncology Pipeline Products 3:01 a.m. Jan. 29, 2014 - Seeking Alpha
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. Jan. 28, 2014 - TheStreet.com
Biotechs - especially Biogen, Celgene, Gilead - have further to rise, DB says 11:58 a.m. Jan. 28, 2014 - Seeking Alpha
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Big cap biotech pushed at Deutsche 9:12 a.m. Jan. 28, 2014 - Seeking Alpha
Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Jan. 28, 2014 - Seeking Alpha
Cramer's Mad Money - We Are In Reset Mode (1/27/14) 5:06 a.m. Jan. 28, 2014 - Seeking Alpha
Growth Portfolio Super Bowl: Gilead Vs. Polaris 12:09 a.m. Jan. 28, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Market Reset 8:33 p.m. Jan. 27, 2014 - TheStreet.com
CHMP Positive on Bayer's Riociguat - Analyst Blog 4:30 p.m. Jan. 27, 2014 - Zacks.com
Top 2013 Drug Approvals: Pharma Stocks 3:58 p.m. Jan. 27, 2014 - Seeking Alpha
Obamacare Boosts Health Funds 11:26 a.m. Jan. 27, 2014 - TheStreet.com
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India 12:30 a.m. Today - PR Newswire - PRF
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014 5:00 p.m. Jan. 28, 2014 - BusinessWire - BZX
Gilead Announces Executive Promotions 5:00 p.m. Jan. 27, 2014 - BusinessWire - BZX
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection 9:09 a.m. Jan. 17, 2014 - BusinessWire - BZX
Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
More positive tests for hep C drug boost AbbVie and Enanta shares 10:52 a.m. Today - blogs.marketwatch.com
Cash ain’t trash 1:55 p.m. Jan. 28, 2014 - The Trading Deck
Beware the dead-cat bounce 1:24 p.m. Jan. 28, 2014 - Michael Ashbaugh
Beware the dead-cat bounce 1:06 p.m. Jan. 28, 2014 - Michael Ashbaugh
The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Are the prevailing technicals bullish, or bearish? 11:54 a.m. Jan. 17, 2014 - Michael Ashbaugh
U.S. stocks drop on Goldman, Citi; Nasdaq edges up 4:07 p.m. Jan. 16, 2014 - Laura Mandaro
Nu Skin sinks on China probe; Best Buy hits 6-month low 4:04 p.m. Jan. 16, 2014 - Ben Eisen
S&P 500 drops from record, but Nasdaq ekes out gain: Stock market live blog recap 4:02 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Speculators turn the heat up to ‘soft boil’ 3:54 p.m. Jan. 16, 2014 - The Trading Deck
Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 3:09 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Earnings boost Micron, drag on Container Store 4:24 p.m. Jan. 8, 2014 - Ben Eisen
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
3 top trades for 2014 6:00 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - blogs.marketwatch.com
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Saumya Vaishampayan
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:18 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
Biotech Sector Performance January 2014 Strong, but What's Ailing Celgene? 2:12 p.m. Today - TheStreet.com
Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences 10:07 a.m. Today - TheStreet.com
Gilead Sciences Inc Retains Buy Recommendation 9:00 a.m. Today - TheStreet.com
Idenix to Raise Funds, Shares up - Analyst Blog 5:20 p.m. Jan. 29, 2014 - Zacks.com
Why Caution Is Prevailing in Biotechs Into and After Earnings 11:29 a.m. Jan. 29, 2014 - 247WallSt.com
UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside 7:35 a.m. Jan. 29, 2014 - 247WallSt.com
Gilead Sciences Inc. (GILD): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 29, 2014 - Zacks.com
6 Biotechnology Stocks to Buy Now 6:00 a.m. Jan. 29, 2014 - InvestorPlace.com
Don't Underestimate Amgen: Part 2A, Cardiovascular And Oncology Pipeline Products 3:01 a.m. Jan. 29, 2014 - Seeking Alpha
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. Jan. 28, 2014 - TheStreet.com
Biotechs - especially Biogen, Celgene, Gilead - have further to rise, DB says 11:58 a.m. Jan. 28, 2014 - Seeking Alpha
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Big cap biotech pushed at Deutsche 9:12 a.m. Jan. 28, 2014 - Seeking Alpha
Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Jan. 28, 2014 - Seeking Alpha
Cramer's Mad Money - We Are In Reset Mode (1/27/14) 5:06 a.m. Jan. 28, 2014 - Seeking Alpha
Growth Portfolio Super Bowl: Gilead Vs. Polaris 12:09 a.m. Jan. 28, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Market Reset 8:33 p.m. Jan. 27, 2014 - TheStreet.com
CHMP Positive on Bayer's Riociguat - Analyst Blog 4:30 p.m. Jan. 27, 2014 - Zacks.com
Top 2013 Drug Approvals: Pharma Stocks 3:58 p.m. Jan. 27, 2014 - Seeking Alpha
Obamacare Boosts Health Funds 11:26 a.m. Jan. 27, 2014 - TheStreet.com
Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India 12:30 a.m. Today - PR Newswire - PRF
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014 5:00 p.m. Jan. 28, 2014 - BusinessWire - BZX
Gilead Announces Executive Promotions 5:00 p.m. Jan. 27, 2014 - BusinessWire - BZX
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection 9:09 a.m. Jan. 17, 2014 - BusinessWire - BZX
Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
(0)
(0)Scroll down for more posts ▼